

FDA BRIEFING DOCUMENT ERRATUM

In Table 4 on page 7 of the Division Director Memorandum, the column headings “Formoterol 24 mcg BID” and “Formoterol 12 mcg BID” are reversed. The corrected Table is as follows:

Table 1. Occurrence of asthma exacerbations, results expressed as number of patients with event (%)

	Formoterol 12 mcg BID (n=527)	Formoterol 24 mcg BID (n=527)	Placebo (n=514)	Formoterol Open-label (n=517)
Serious asthma-related adverse events	5 (0.9%)	2 (0.4%)	1 (0.2%)	1 (0.2%)
Serious asthma exacerbations	3 (0.6%)	2 (0.4%)	1 (0.2%)	1 (0.2%)